The US Food and Drug Administration (FDA) has agreed on biopharmaceutical firm Chiasma’s new Phase III clinical trial (OPTIMAL) design to evaluate its octreotide capsules product candidate Mycapssa as a maintenance therapy to treat adults with acromegaly.

Developed using the firm’s Transient Permeability Enhancer (TPE) technology platform, the octreotide capsules are intended to bind to receptors on specialised cells in the pituitary gland for minimising growth hormone (GH) production.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

The new trial design will address previous concerns raised by the FDA in April last year, when the agency advised the firm to perform an additional clinical trial to obtain substantial evidence of the product candidate’s efficacy.

Chiasma reached the trial design agreement through Special Protocol Assessment (SPA) with the FDA’s Metabolism and Endocrinology Products division.

“It is a critical milestone in the continued development of octreotide capsules and provides regulatory clarity to enable us to resubmit our new drug application (NDA) if the trial’s primary endpoint is achieved.”

Planned to enrol 50 patients, the randomised, double-blind, placebo-controlled, nine-month OPTIMAL trial will measure the levels of IGF-1 growth factor as the primary endpoint.

Chiasma president and CEO Mark Fitzpatrick said: “The SPA indicates the agency’s agreement that our planned new Phase III clinical trial is appropriately designed to form the primary basis of an efficacy claim.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

“It is a critical milestone in the continued development of octreotide capsules and provides regulatory clarity to enable us to resubmit our new drug application (NDA) if the trial’s primary endpoint is achieved.”

During the Phase III trial, subjects will be dose titrated from 40mg per day up to 80mg per day, equivalent to two capsules in the morning and two capsules in the evening.

Enrolment for the trial is expected to begin in the coming months and the top-line results are expected to be reported by the end of 2019.